Center for Therapeutic Innovation (CTI)
Current News:
Pre-proposal Due November 4th, 2011
Information about the funded programs from the first round of funding.
As you may have heard, UCSF and Pfizer, Inc. have formed a new partnership to accelerate the translation of biomedical research into effective new medications and therapies for patients. This is one of several Pfizer Centers for Therapeutic Innovation (CTI) throughout the world, and we are pleased that UCSF was chosen to be the first CTI to be launched.
This is a innovative approach to industry partnerships and offers enormous benefits for our researchers. Each of the individual projects will include milestone payments, broad publishing rights and the ability to use all intellectual property, joint or otherwise, for research purposes.
We have already initiated 5 funded programs this year, in areas ranging from cardiovascular and pulmonary disease, to oncology and fatty liver disease.
New call for Proposals! Due November 4th, 2011!
We anticipate initiating at least 2-3 new UCSF-CTI projects for this funding cycle. Projects within the CTI are expected to identify novel molecules that can be targeted by biologics and to build on the existing understanding on the new target biology, and translational medicine expertise that resides with the Principal Investigator (PI) and at UCSF. Joint partnership with scientists at Pfizer will bring the drug discovery engine and proprietary technologies available at Pfizer to the project. The UCSF-CTI center will focus on biotherapeutic modalities (antibodies, peptides, proteins) across all therapeutic areas with the goal of rapid translation of a mechanism derived from preclinical work to the clinic.For further details on the program, proposal process and guidelines please see following documents:
We look forward to your submissions.
Please contact ita@ucsf.edu with any questions.